

---

## REFERENCES

- (1) Herculano-Houzel, S. The human brain in numbers: a linearly scaled-up primate brain. *Front. Hum. Neurosci.* **2009**, *3*.
- (2) Lodish H.; Berk A.; Zipursky, S. L. Neurotransmitters, synapses, and impulse transmission. In *Molecular Cell Biology*, 4<sup>th</sup> edition; W. H. Freeman: New York, **2000**.
- (3) Kumar, A.; Foster, T. C. Neurophysiology of old neurons and synapses. In *Brain Aging: models, methods, and mechanisms.* **2007**, 229–250.
- (4) Vangavaragu, J. R.; Vissavajhala, P.; Damodar Reddy, C. Alzheimer's disease: current perspectives-animal models, drugs under development, and potential nutritional intervention. In *Foods and Dietary Supplements in the Prevention and Treatment of Disease in Older Adults.* **2015**, 13–28.
- (5) Cunningham, E. L.; McGuinness, B.; Herron, B.; Passmore, A. P. Dementia. *Ulster Med. J.* **2015**, *84*, 79–87.
- (6) Ayuso Peralta, L.; Ballesteros Barranco, A.; Rojo Sebastián, A. Dementia. *Med.* **2019**, *12*, 4329–4337.
- (7) Hippus, H.; Neundörfer, G. The discovery of Alzheimer's disease. *Dialogues Clin. Neurosci.* **2003**, *5*, 101–108.
- (8) Christina Patterson. World Alzheimer report 2018: the state of the art of dementia research. *New Frontiers.* **2018**.
- (9) Rizzi, L.; Rosset, I.; Roriz-Cruz, M. Global epidemiology of dementia: Alzheimer's and vascular types. *Biomed Res. Int.* **2014**.
- (10) Talesa, V. N. Acetylcholinesterase in Alzheimer's disease. *Mech. Ageing Dev.* **2001**, *122*, 1961–1969.
- (11) Hardy, J. A.; Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. *Science.* **1992**, *256*, 184–185.
- (12) Chu, D.; Liu, F. Pathological changes of tau related to Alzheimer's disease. *ACS Chem. Neurosci.* **2019**, *10*, 931–944.

- 
- (13) Price, J. L.; Davis, P. B.; Morris, J. C.; White, D. L. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. *Neurobiol. Aging*. **1991**, *12*, 295–312.
  - (14) 2019 Alzheimer's disease facts and figures. *Alzheimer's Dement. J. Alzheimer's Assoc.* **2019**, *15*, 321–387.
  - (15) <https://www.medicalnewstoday.com/articles/315123> (accessed on 03.01.2020).
  - (16) <https://www.medicalnewstoday.com/articles/159442> (accessed on 03.01.2020).
  - (17) Craig, L. A.; Hong, N. S.; McDonald, R. J. Revisiting the cholinergic hypothesis in the development of Alzheimer's disease. *Neurosci. Biobehav. Rev.* **2011**, *35*, 1397–1409.
  - (18) Kanwar, J.; Tiwari, M. Development of a benzothiazole derivative as potential multi-targeted directed ligand for therapy of Alzheimer's disease. **2019**.
  - (19) Greig, N. H.; Lahiri, D. K.; Sambamurti, K. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. *Int. Psychogeriatrics*. **2002**, *14*, 77–91.
  - (20) Jing, L.; Wu, G.; Kang, D.; Zhou, Z.; Song, Y.; Liu, X.; Zhan, P. Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors. *Drug Discov. Today* **2019**, *24*, 629–635.
  - (21) Sussman, J. L.; Harel, M.; Frolow, F.; Oefner, C.; Goldman, A.; Toker, L.; Silman, I. Atomic structure of acetylcholinesterase from *Torpedo californica*: a prototypic acetylcholine-binding protein. *Science*. **1991**, *253*, 872–879.
  - (22) Dinamarca, M. C.; Sagal, J. P.; Quintanilla, R. A.; Godoy, J. A.; Arrzola, M. S.; Inestrosa, N. C. Amyloid- $\beta$ -acetylcholinesterase complexes potentiate neurodegenerative changes induced by the a peptide. implications for the pathogenesis of Alzheimer's disease. *Mol. Neurodegener.* **2010**, *5*.

- 
- (23) De Ferrari, G. V.; Canales, M. A.; Shin, I.; Weiner, L. M.; Silman, I.; Inestrosa, N. C. A structural motif of acetylcholinesterase that promotes amyloid  $\beta$ -peptide fibril formation. *Biochemistry*. **2001**, *40*, 10447–10457.
- (24) Wang, Y.; Wang, H.; Chen, H. AChE inhibition-based multi-target-directed ligands, a novel pharmacological approach for the symptomatic and disease-modifying therapy of Alzheimer's disease. *Curr. Neuropharmacol.* **2016**, *14*, 364–375.
- (25) Hartmann, J.; Kiewert, C.; Duysen, E. G.; Lockridge, O.; Greig, N. H.; Klein, J. Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. *J. Neurochem.* **2007**, *100*, 1421–1429.
- (26) Guillozet, A. L.; Smiley, J. F.; Mash, D. C.; Mesulam, M. M. Butyrylcholinesterase in the life cycle of amyloid plaques. *Ann. Neurol.* **1997**, *42*, 909–918.
- (27) J, B. Cholinesterase inhibitors (ChEIs), donepezil, galantamine and rivastigmine are efficacious for mild to moderate Alzheimer's disease. **2012**.
- (28) O'Brien R. J.; Wong P. C. Amyloid precursor protein processing and Alzheimer's disease. *Annu Rev Neurosci.* **2011**, *34*, 185–204.
- (29) Zhang, C. Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer's disease. *Discov. Med.* **2012**, *14*, 189–197.
- (30) Cetin, F. Role of oxidative stress in A $\beta$  animal model of Alzheimer's disease: vicious circle of apoptosis, nitric oxide and age. In *Neurodegenerative Diseases*. **2013**.
- (31) Hardy, J. A.; Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. *Science*. **1992**, *256*, 184–185.
- (32) Barbier, P.; Zejneli, O.; Martinho, M.; Lasorsa, A.; Belle, V.; Smet-Nocca, C.; Tsvetkov, P. O.; Devred, F.; Landrieu, I. Role of tau as a microtubule-associated protein: structural and functional aspects. *Front. Aging Neurosci.* **2019**, *10*, 204.
-

- 
- (33) Kontaxi, C.; Piccardo, P.; Gill, A. C. Lysine-directed post-translational modifications of tau protein in Alzheimer's disease and related tauopathies. *Front. Mol. Biosci.* **2017**, *4*, 56.
- (34) Havoutis, G. H. Analysis of diagnostic, preventive, and disease-modifying therapeutic measures of Alzheimer's disease. *Medicine.* **2017**.
- (35) Iqbal, K.; Liu, F.; Gong, C. X.; Grundke-Iqbal, I. Tau in Alzheimer disease and related tauopathies. *Curr. Alzheimer Res.* **2010**, *7*, 656–664.
- (36) Perry, G.; Cash, A. D.; Smith, M. A. Alzheimer disease and oxidative stress. *J. Biomed. Biotechnol.* **2002**, 120–123.
- (37) Smith, M. A.; Rottkamp, C. A.; Nunomura, A.; Raina, A. K.; Perry, G. Oxidative stress in Alzheimer's disease. *Biochim. Biophys. Acta - Mol. Basis Dis.* **2000**, *1502*, 139–144.
- (38) Collin, F. Chemical basis of reactive oxygen species reactivity and involvement in neurodegenerative diseases. *Int. J. Mol. Sci.* **2019**, *20*, 2407.
- (39) Liu, Y.; Nguyen, M.; Robert, A.; Meunier, B. Metal ions in Alzheimer's disease: a key role or not? *Acc. Chem. Res.* **2019**, *52*, 2026–2035.
- (40) Garza-Lombó, C.; Posadas, Y.; Quintanar, L.; Gonsebatt, M. E.; Franco, R. Neurotoxicity linked to dysfunctional metal ion homeostasis and xenobiotic metal exposure: redox signaling and oxidative stress. *Antioxid. Redox Sign.* **2018**, *28*, 1669–1703.
- (41) Duce, J. A.; Bush, A. I.; Adlard, P. A. Role of amyloid- $\beta$ -metal interactions in Alzheimers disease. *Future Neurol.* **2011**, *6*, 641–659.
- (42) Kim, A. C.; Lim, S.; Kim, Y. K. Metal ion effects on A $\beta$  and tau aggregation. *Int. J. Mol. Sci.* **2018**, *19*, 128.
- (43) Drew, S. C.; Barnham, K. J. The heterogeneous nature of Cu<sup>2+</sup> interactions with Alzheimer's amyloid- $\beta$  peptide. *Acc. Chem. Res.* **2011**, *44*, 1146–1155.
- (44) Atwood, C. S.; Huang, X.; Moir, R. D.; Tanzi, R. E.; Bush, A. I. Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. In *Metal ions in biological systems.* **2018**. 309-364.

- 
- (45) Adlard, P. A.; Bush, A. I. Metals and Alzheimer's disease: how far have we come in the clinic? *J. Alzheimer's Dis.* **2018**, *62* (3), 1369–1379.
- (46) Gorantla, N. V; Landge, V. G.; Nagaraju, P. G.; Sunny, L. P. Molecular complexes for effective inhibition of tau aggregation. **2018**, 1–33.
- (47) Esposito, Z.; Belli, L.; Toniolo, S.; Sancesario, G.; Bianconi, C.; Martorana, A. Amyloid  $\beta$ , glutamate, excitotoxicity in Alzheimer's disease: are we on the right track? *CNS Neurosci. Ther.* **2013**, *19*, 549–555.
- (48) Obulesu, M.; Lakshmi, M. J. Apoptosis in Alzheimer's disease: an understanding of the physiology, pathology and therapeutic avenues. *Neurochem. Res.* **2014**, *39*, 2301–2312.
- (49) Sawikr, Y.; Yarla, N. S.; Peluso, I.; Kamal, M. A.; Aliev, G.; Bishayee, A. Neuroinflammation in Alzheimer's disease: the preventive and therapeutic potential of polyphenolic nutraceuticals. *Adv. Protein Chem. Struct. Biol.* **2017**, *108*, 33–57.
- (50) Singh, M.; Kaur, M.; Chadha, N.; Silakari, O. Hybrids: a new paradigm to treat Alzheimer's disease. *Mol. Divers.* **2016**, *20*, 271–297.
- (51) Carmo Carreiras, M.; Mendes, E.; Jesus Perry, M.; Paula Francisco, A.; Marco-Contelles, J. The multifactorial nature of Alzheimer's disease for developing potential therapeutics. *Curr. Top. Med. Chem.* **2013**, *13*, 1745–1770.
- (52) Watkins, P. B.; Zimmerman, H. J.; Knapp, M. J.; Gracon, S. I.; Lewis, K. W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. *J. Am. Med. Assoc.* **1994**, *271*, 992–998.
- (53) Birks, J. S.; Harvey, R. J. Donepezil for dementia due to Alzheimer's disease. *Cochrane Database Syst. Rev.* **2018**.
- (54) Loy, C.; Schneider, L. Galantamine for Alzheimer's disease. *Cochrane Database Syst. Rev.* **2004**.
- (55) Birks, J. S.; Grimley Evans, J. Rivastigmine for Alzheimer's disease. *Cochrane Database Syst. Rev.* **2015**.

- 
- (56) McShane, R.; Westby, M. J.; Roberts, E.; Minakaran, N.; Schneider, L.; Farrimond, L. E.; Maayan, N.; Ware, J.; Debarros, J. Memantine for dementia. *Cochrane Database Syst. Rev.* **2019**, 1–446.
- (57) Agis-Torres, A.; Sollhuber, M.; Fernandez, M.; Sanchez-Montero, J. M. Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer’s disease. *Curr. Neuropharmacol.* **2014**, *12*, 2–36.
- (58) Bajda, M.; Guzior, N.; Ignasik, M.; Malawska, B. Multi-target-directed ligands in Alzheimer’s disease treatment. *Curr. Med. Chem.* **2011**, *18*, 4949–4975.
- (59) Oset-Gasque, M. J.; Marco-Contelles, J. Alzheimer’s disease, the “one-molecule, one-target” paradigm, and the multitarget directed ligand approach. *ACS Chem. Neurosci.* **2018**, *9*, 401–403.
- (60) Richard Morphy, J. The challenges of multi-target lead optimization. *Designing Multi-Target Drugs.* **2012**, 141–154.
- (61) Csermely, P.; Ágoston, V.; Pongor, S. The efficiency of multi-target drugs: the network approach might help drug design. *Trends Pharmacol. Sci.* **2005**, *26*, 178–182.
- (62) Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. *J. Med. Chem.* **2008**, *51*, 2326–2326.
- (63) Sharma, V.; Kumar, P.; Pathaka, D. Biological importance of the indole nucleus in recent years: a comprehensive review. *J. Heterocycl. Chem.* **2010**, *47*, 491–502.
- (64) Wu, Y. H.; Feenstra, M. G. P.; Zhou, J. N.; Liu, R. Y.; Toranõ, J. S.; Van Kan, H. J. M.; Fischer, D. F.; Ravid, R.; Swaab, D. F. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. *J. Clin. Endocrinol. Metab.* **2003**, *88*, 5898–5906.
- (65) Pandi-Perumal, S. R.; Srinivasan, V.; Maestroni, G. J. M.; Cardinali, D. P.; Poeggeler, B.; Hardeland, R. Melatonin: nature’s most versatile biological signal? *FEBS J.* **2006**, *273*, 2813–2838.
-

- 
- (66) Feng, Z.; Qin, C.; Chang, Y.; Zhang, J. T. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. *Free Radic. Biol. Med.* **2006**, *40*, 101–109.
- (67) Espinar, A.; García-Oliva, A.; Isorna, E. M.; Quesada, A.; Prada, F. A.; Guerrero, J. M. Neuroprotection by melatonin from glutamate-induced excitotoxicity during development of the cerebellum in the chick embryo. *J. Pineal Res.* **2000**, *28*, 81–88.
- (68) Rodríguez-Franco, M. I.; Fernández-Bachiller, M. I.; Pérez, C.; Hernández-Ledesma, B.; Bartolomé, B. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. *J. Med. Chem.* **2006**, *49*, 459–462.
- (69) Yanovsky, I.; Finkin-Groner, E.; Zaikin, A.; Lerman, L.; Shalom, H.; Zeeli, S.; Weill, T.; Ginsburg, I.; Nudelman, A.; Weinstock, M. Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease. *J. Med. Chem.* **2012**, *55*, 10700–10715.
- (70) Pachón-Angona, I.; Refouvelet, B.; Andrys, R.; Martin, H.; Luzet, V.; Iriepa, I.; Moraleda, I.; Diez-Iriepa, D.; Oset-Gasque, M. J.; Marco-Contelles, J. Donepezil-chromone-melatonin hybrids as promising agents for Alzheimer's disease therapy. *J. Enzyme Inhib. Med. Chem.* **2019**, *34*, 479–489.
- (71) Fang, L.; Chen, M.; Liu, Z.; Fang, X.; Gou, S.; Chen, L. Ferulic acid-carbazole hybrid compounds: combination of cholinesterase inhibition, antioxidant and neuroprotection as multifunctional anti-Alzheimer agents. *Bioorg. Med. Chem.* **2016**, *24*, 886–893.
- (72) Yang, W.; Wong, Y.; Ng, O. T. W.; Bai, L. P.; Kwong, D. W. J.; Ke, Y.; Jiang, Z. H.; Li, H. W.; Yung, K. K. L.; Wong, M. S. Inhibition of beta-amyloid peptide aggregation by multifunctional carbazole-based fluorophores. *Angew. Chemie - Int. Ed.* **2012**, *51*, 1804–1810.
- (73) Fang, L.; Fang, X.; Gou, S.; Lupp, A.; Lenhardt, I.; Sun, Y.; Huang, Z.; Chen, Y.; Zhang, Y.; Fleck, C. Design, synthesis and biological

- 
- evaluation of D-ring opened galantamine analogs as multifunctional anti-Alzheimer agents. *Eur. J. Med. Chem.* **2014**, *76*, 376–386.
- (74) Bertini, S.; Ghilardi, E.; Asso, V.; Minutolo, F.; Rapposelli, S.; Digiacomo, M.; Saccomanni, G.; Salmaso, V.; Sturlese, M.; Moro, S. Sulfonamido-derivatives of unsubstituted carbazoles as BACE1 inhibitors. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 4812–4816.
- (75) Songsiang, U.; Thongthoom, T.; Boonyarat, C.; Yenjai, C. Claurailas A-D, cytotoxic carbazole alkaloids from the roots of *Clausena harmandiana*. *J. Nat. Prod.* **2011**, *74*, 208–212.
- (76) Thiratmatrakul, S.; Yenjai, C.; Waiwut, P.; Vajragupta, O.; Reubroycharoen, P.; Tohda, M.; Boonyarat, C. Synthesis, biological evaluation and molecular modeling study of novel tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease. *Eur. J. Med. Chem.* **2014**, *75*, 21–30.
- (77) Choubdar, N.; Golshani, M.; Jalili-Baleh, L.; Nadri, H.; Küçükkinilç, T. T.; Ayazgök, B.; Moradi, A.; Moghadam, F. H.; Abdolahi, Z.; Ameri, A. New classes of carbazoles as potential multi-functional anti-Alzheimer's agents. *Bioorg. Chem.* **2019**, *91*, 103164.
- (78) Zhang, X.; Wang, Y.; Wang, S. N.; Chen, Q. H.; Tu, Y. L.; Yang, X. H.; Chen, J. K.; Yan, J. W.; Pi, R. B.; Wang, Y. discovery of a novel multifunctional carbazole-aminoquinoline dimer for Alzheimer's disease: copper selective chelation, anti-amyloid aggregation, and neuroprotection. *Med. Chem. Res.* **2018**, *27*, 777–784.
- (79) Makhaeva, G. F.; Shevtsova, E. F.; Kovaleva, N. V.; Rudakova, E. V.; Neganova, M. E.; Dubova, L. G.; Shevtsov, P. N.; Aksinenko, A. Y.; Sokolov, V. B.; Bachurin, S. O. Aminoadamantane conjugates with carbazole derivatives as potential multitarget agents for the treatment of Alzheimer's disease. effect of the spacer structure. *Russ. Chem. Bull.* **2018**, *67*, 2121–2126.
- (80) Ghobadian, R.; Esfandyari, R.; Nadri, H.; Moradi, A.; Mahdavi, M.; Akbarzadeh, T.; Khaleghzadeh-Ahangar, H.; Edraki, N.; Sharifzadeh, M.; Amini, M. Design, synthesis, *in vivo* and *in vitro* studies of 1,2,3,4-

- 
- tetrahydro-9*H*-carbazole derivatives, highly selective and potent butyrylcholinesterase inhibitors. *Mol. Divers.* **2019**, 1-13.
- (81) Hong, M. C.; Kim, Y. K.; Choi, J. Y.; Yang, S. Q.; Rhee, H.; Ryu, Y. H.; Choi, T. H.; Cheon, G. J.; An, G. I.; Kim, H. Y.; Synthesis and evaluation of stilbene derivatives as a potential imaging agent of amyloid plaques. *Bioorg. Med. Chem.* **2010**, *18*, 7724–7730.
- (82) Cheng, G.; Xu, P.; Zhang, M.; Chen, J.; Sheng, R.; Ma, Y. Resveratrol-maltol hybrids as multi-target-directed agents for Alzheimer's disease. *Bioorg. Med. Chem.* **2018**, *26*, 5759–5765.
- (83) Lu, C.; Guo, Y.; Li, J.; Yao, M.; Liao, Q.; Xie, Z.; Li, X. Design, synthesis, and evaluation of resveratrol derivatives as A $\beta$ <sub>1-42</sub> aggregation inhibitors, antioxidants, and neuroprotective agents. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 7683–7687.
- (84) Li, Y.; Qiang, X.; Li, Y.; Yang, X.; Luo, L.; Xiao, G.; Cao, Z.; Tan, Z.; Deng, Y. Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti- $\beta$ -amyloid aggregation and antioxidant properties for the treatment of Alzheimer's disease. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 2035–2039.
- (85) Zheng, Y.; Qiang, X.; Xu, R.; Song, Q.; Tian, C.; Liu, H.; Li, W.; Tan, Z.; Deng, Y. Design, synthesis and evaluation of pterostilbene  $\beta$ -amino alcohol derivatives as multifunctional agents for Alzheimer's disease treatment. *Bioorg. Chem.* **2018**, *78*, 298–306.
- (86) Wang, X. Q.; Xia, C. L.; Chen, S. Bin; Tan, J. H.; Ou, T. M.; Huang, S. L.; Li, D.; Gu, L. Q.; Huang, Z. S. Design, synthesis, and biological evaluation of 2-arylethenylquinoline derivatives as multifunctional agents for the treatment of Alzheimer's disease. *Eur. J. Med. Chem.* **2015**, *89*, 349–361.
- (87) Xia, C. L.; Wang, N.; Guo, Q. L.; Liu, Z. Q.; Wu, J. Q.; Huang, S. L.; Ou, T. M.; Tan, J. H.; Wang, H. G.; Li, D. Design, synthesis and evaluation of 2-arylethenyl-*N*-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment. *Eur. J. Med. Chem.* **2017**, *130*, 139–153.

- 
- (88) Tang, Y. W.; Shi, C. J.; Yang, H. L.; Cai, P.; Liu, Q. H.; Yang, X. L.; Kong, L. Y.; Wang, X. B. Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer's disease. *Eur. J. Med. Chem.* **2019**, *163*, 307–319.
- (89) Sinha, A.; Tamboli, R. S.; Seth, B.; Kanhed, A. M.; Tiwari, S. K.; Agarwal, S.; Nair, S.; Giridhar, R.; Chaturvedi, R. K.; Yadav, M. R. Neuroprotective role of novel triazine derivatives by activating Wnt/ $\beta$  catenin signaling pathway in rodent models of Alzheimer's disease. *Mol. Neurobiol.* **2015**, *52*, 638–652.
- (90) Leong, S. W.; Abas, F.; Lam, K. W.; Shaari, K.; Lajis, N. H. 2-Benzoyl-6-benzylidenecyclohexanone analogs as potent dual inhibitors of acetylcholinesterase and butyrylcholinesterase. *Bioorg. Med. Chem.* **2016**, *24*, 3742-3751.
- (91) Liu, Q.; Qiang, X.; Li, Y.; Sang, Z.; Li, Y.; Tan, Z.; Deng, Y. Design, synthesis and evaluation of chromone-2-carboxamido-alkylbenzylamines as multifunctional agents for the treatment of Alzheimer's disease. *Bioorg. Med. Chem.* **2015**, *23*, 911-923.
- (92) Gao, X. H.; Tang, J. J.; Liu, H. R.; Liu, L. B.; Liu, Y. Z. Structure-activity study of fluorine or chlorine-substituted cinnamic acid derivatives with tertiary amine side chain in acetylcholinesterase and butyrylcholinesterase inhibition. *Drug Dev. Res.* **2019**, *80*, 438–445.
- (93) Sonmez, F.; Zengin Kurt, B.; Gazioglu, I.; Basile, L.; Dag, A.; Cappello, V.; Ginex, T.; Kucukislamoglu, M.; Guccione, S. Design, synthesis and docking study of novel coumarin ligands as potential selective acetylcholinesterase inhibitors. *J. Enzyme Inhib. Med. Chem.* **2017**, *32*, 285-297.
- (94) Shamsimeymandi, R.; Pourshojaei, Y.; Eskandari, K.; Mohammadi-Khanaposhtani, M.; Abiri, A.; Khodadadi, A.; Langarizadeh, A.; Sharififar, F.; Amirheidari, B.; Akbarzadeh, T. Design, synthesis, biological evaluation, and molecular dynamics of novel cholinesterase inhibitors as anti-Alzheimer's agents. *Arch. Pharm. (Weinheim).* **2019**, *352*.

- 
- (95) Tehrani, M. B.; Rezaei, Z.; Asadi, M.; Behnammanesh, H.; Nadri, H.; Afsharirad, F.; Moradi, A.; Larijani, B.; Mohammadi-Khanaposhtani, M.; Mahdavi, M. Design, synthesis, and cholinesterase inhibition assay of coumarin-3-carboxamide-*N*-morpholine hybrids as new anti-Alzheimer agents. *Chem. Biodivers.* **2019**, *16*.
- (96) Mecocci, P.; Polidori, M. C. Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. *Biochim. Biophys. Acta - Mol. Basis Dis.* **2012**, *1822*, 631–638.
- (97) Kaushik, N. K.; Kaushik, N.; Attri, P.; Kumar, N.; Kim, C. H.; Verma, A. K.; Choi, E. H. Biomedical importance of indoles. *Molecules.* **2013**, *18*, 6620–6662.
- (98) Zhou, J. N.; Liu, R. Y.; Kamphorst, W.; Hofman, M. A.; Swaab, D. F. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. *J. Pineal Res.* **2003**, *35*, 125–130.
- (99) Feng, Z.; Zhang, J. T. Melatonin reduces amyloid  $\beta$ -induced apoptosis in pheochromocytoma (PC12) cells. *J. Pineal Res.* **2004**, *37*, 257–266.
- (100) Aydogan, S.; Betul Yerer, M.; Goktas, A. Melatonin and nitric oxide. *J. Endocrinol. Invest.* **2006**, *29*, 281–287.
- (101) Pachón-Angona, I.; Refouvelet, B.; Andrýs, R.; Martin, H.; Luzet, V.; Iriepa, I.; Musilek, K. Donepezil-chromone-melatonin hybrids as promising agents for Alzheimer's disease therapy. *J. Enzyme Inhib. Med. Chem.* **2019**, *34*, 479–489.
- (102) López-Iglesias, B.; Pérez, C.; Morales-García, J. A.; Alonso-Gil, S.; Pérez-Castillo, A.; Romero, A.; López, M. G.; Villarroja, M.; Conde, S.; Rodríguez-Franco, M. I. New melatonin-*N,N*-dibenzyl(*N*-methyl) amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimers disease. *J. Med. Chem.* **2014**, *57*, 3773–3785.
- (103) Kumar, R.; Sirohi, T. S.; Singh, H.; Yadav, R.; Roy, R. K.; Chaudhary, A.; Pandeya, S. N. 1,2,4-Triazine analogs as novel class of therapeutic agents. *Mini Rev. Med. Chem.* **2014**, *14*, 168–207.
-

- 
- (104) Irannejad, H.; Amini, M.; Khodaghali, F.; Ansari, N.; Tusi, S. K.; Sharifzadeh, M.; Shafiee, A. Synthesis and *in vitro* evaluation of novel 1,2,4-triazine derivatives as neuroprotective agents. *Bioorg. Med. Chem.* **2010**, *18*, 4224–4230.
- (105) Veloso, A. J.; Chow, A. M.; Dhar, D.; Tang, D. W. F.; Ganesh, H. V. S.; Mikhaylichenko, S.; Brown, I. R.; Kerman, K. Biological activity of *sym*-triazines with acetylcholine-like substitutions as multitarget modulators of Alzheimer's disease. *ACS Chem. Neurosci.* **2013**, *4*, 924–929.
- (106) Russell, M. G. N.; Carling, R. W.; Street, L. J.; Hallett, D. J.; Goodacre, S.; Mezzogori, E.; Reader, M.; Cook, S. M.; Bromidge, F. A.; Newman, R. Discovery of imidazo[1,2-*b*][1,2,4]triazines as GABAA A2/3 subtype selective agonists for the treatment of anxiety. *J. Med. Chem.* **2006**, *49*, 1235–1238.
- (107) Leach, M. J.; Marden, C. M.; Miller, A. A. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. neurochemical studies on the mechanism of action. *Epilepsia* **1986**, *27*, 490–497.
- (108) Misra, U.; Hitkari, A.; Saxena, A. K.; Gurtu, S.; Shanker, K. Biologically active indolylmethyl-1,3,4-oxadiazoles, 1,3,4-thiadiazoles, 4*H*-1,3,4-triazoles and 1,2,4-triazines. *Eur. J. Med. Chem.* **1996**, *31*, 629–634.
- (109) Ansari, N.; Khodaghali, F.; Ramin, M.; Amini, M.; Irannejad, H.; Dargahi, L.; Amirabad, A. D. Inhibition of LPS-induced apoptosis in differentiated-PC12 cells by new triazine derivatives through NF- $\kappa$ B-mediated suppression of COX-2. *Neurochem. Int.* **2010**, *57*, 958–968.
- (110) Tamboli, R. S.; Giridhar, R.; Gandhi, H. P.; Kanhed, A. M.; Mande, H. M.; Yadav, M. R. Design, green synthesis and pharmacological evaluation of novel 5,6-diaryl-1,2,4-triazines bearing 3-morpholinoethylamine moiety as potential antithrombotic agents. *J. Enzyme Inhib. Med. Chem.* **2016**, *31*, 704–713.
- (111) El Ashry, E. S. H.; Ramadan, E. S.; Abdel Hamid, H. M.; Hagar, M. Microwave irradiation for accelerating each step for the synthesis of 1,2,4-triazino[5,6-*b*]indole-3-thiols and their derivatives from isatin and 5-chloroisatin. *Synlett* **2004**, *4*, 723–725.

- 
- (112) Gianella-Borradori, M.; Christou, I.; Bataille, C. J. R.; Cross, R. L.; Wynne, G. M.; Greaves, D. R.; Russell, A. J. Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists. *Bioorg. Med. Chem.* **2015**, *23*, 241–263.
- (113) Taylor, E. C.; Macor, J. E.; Pont, J. L. Intramolecular diels-alder reactions of 1,2,4-triazines. a general synthesis of furo[2,3-*b*]pyridinfs, 2,3-dihydropyrano[2,3-*b*]yridines, and pyrrolo[2,3-*b*]pyridine. *Tetrahedron.* **1987**, *43*, 2–15.
- (114) Hou, D. R.; Cheng, H. Y.; Wang, E. C. Efficient syntheses of oncinotine and neooncinotine. *J. Org. Chem.* **2004**, *69*, 6094–6099.
- (115) Shidore, M.; Machhi, J.; Shingala, K.; Murumkar, P.; Sharma, M. K.; Agrawal, N.; Tripathi, A.; Parikh, Z.; Pillai, P.; Yadav, M. R. Benzylpiperidine-linked diarylthiazoles as potential anti-Alzheimer's agents: synthesis and biological evaluation. *J. Med. Chem.* **2016**, *59*, 5823–5846.
- (116) Sinha, A.; Tamboli, R. S.; Seth, B.; Kanhed, A. M.; Tiwari, S. K.; Agarwal, S.; Nair, S.; Giridhar, R.; Chaturvedi, R. K.; Yadav, M. R. Correction to: neuroprotective role of novel triazine derivatives by activating wnt/ $\beta$  catenin signaling pathway in rodent models of Alzheimer's disease. *Mol. Neurobiol.* **2019**, *56*, 7246–7248.
- (117) Kanhed, A. M.; Sinha, A.; Machhi, J.; Tripathi, A.; Parikh, Z. S.; Pillai, P. P.; Giridhar, R.; Yadav, M. R. Discovery of isoalloxazine derivatives as a new class of potential anti-Alzheimer agents and their synthesis. *Bioorg. Chem.* **2015**, *61*, 7–12.
- (118) Kanhed, A.M. Computational designing of some novel enzyme inhibitors. PhD thesis, The M. S. University of Baroda, India, **2015**.
- (119) Saxena, A.; Redman, A. M. G.; Jiang, X.; Lockridge, O.; Doctor, B. P. Differences in active-site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. *Chem. Biol. Interact.* **1999**, *119–120*, 61–69.
- (120) Kedare, S. B.; Singh, R. P. Genesis and development of DPPH method of antioxidant assay. *J. Food Sci. Technol.* **2011**, *48*, 412–422.

- 
- (121) Mathew, M.; Subramanian, S. *In vitro* screening for anti-cholinesterase and antioxidant activity of methanolic extracts of ayurvedic medicinal plants used for cognitive disorders. *PLoS One*. **2014**, *9*, 1–7.
- (122) Porcal, W.; Hernández, P.; González, M.; Ferreira, A.; Olea-Azar, C.; Cerecetto, H.; Castro, A. Heteroaryl nitrones as drugs for neurodegenerative diseases: synthesis, neuroprotective properties, and free radical scavenger properties. *J. Med. Chem.* **2008**, *51*, 6150–6159.
- (123) Roland, J. R.; Jacobsen, H. Alzheimer's disease: from pathology to therapeutic approaches. *Angew. Chemie - Int. Ed.* **2009**, *48*, 3030–3059.
- (124) Dahlgren, K. N.; Manelli, A. M.; Blaine Stine, W.; Baker, L. K.; Krafft, G. A.; Ladu, M. J. Oligomeric and fibrillar species of amyloid- $\beta$  peptides differentially affect neuronal viability. *J. Biol. Chem.* **2002**, *277*, 32046–32053.
- (125) Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput artificial membrane permeability assay for blood-brain barrier. *Eur. J. Med. Chem.* **2003**, *38*, 223–232.
- (126) Psimadas, D.; Georgoulis, P.; Valotassiou, V.; Loudos, G. Molecular nanomedicine towards cancer : *J. Pharm. Sci.* **2012**, *101*, 2271–2280.
- (127) Chen, J.; Long, Y.; Han, M.; Wang, T.; Chen, Q.; Wang, R. Water-soluble derivative of propolis mitigates scopolamine-induced learning and memory impairment in mice. *Pharmacol. Biochem. Behav.* **2008**, *90*, 441–446.
- (128) Lee, M. R.; Yun, B. S.; Park, S. Y.; Ly, S. Y.; Kim, S. N.; Han, B. H.; Sung, C. K. Anti-amnesic effect of Chong-Myung-Tang on scopolamine-induced memory impairments in mice. *J. Ethnopharmacol.* **2010**, *132*, 70–74.
- (129) Goverdhan, P.; Sravanthi, A.; Mamatha, T. Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress. *Int. J. Alzheimers. Dis.* **2012**.
- (130) Morris, R. Developments of a water-maze procedure for studying spatial learning in the rat. *J. Neurosci. Methods* **1984**, *11*, 47–60.

- 
- (131) OECD. Test No. 423: Acute oral toxicity - acute toxic class method. **2002**.
- (132) Protein Data Bank, [www.rcsb.org/pdb/home/home.do](http://www.rcsb.org/pdb/home/home.do) (accessed Jan. 09, 2019).
- (133) Tuckerman, M.; Berne, B. J.; Martyna, G. J. Reversible multiple time scale molecular dynamics. *J. Chem. Phys.* **1992**, *97*, 1990–2001.
- (134) Bowers, K. J.; Chow, D. E.; Xu, H.; Dror, R. O.; Eastwood, M. P.; Gregersen, B. A.; Klepeis, J. L.; Kolossvary, I.; Moraes, M. A.; Sacerdoti, F. D.; Scalable algorithms for molecular dynamics simulations on commodity clusters. *Proceedings of the 2006 ACM/IEEE Conference on Supercomputing.* **2007**, 43–43.
- (135) Jianling Wang; Laszlo Urban. The impact of early ADME profiling on drug discovery and development strategy. *Drug Discov. World.* **2004**, 73–86.
- (136) QikProp, version 3.5, Schrödinger, LLC, New York, **2012**.
- (137) Dong, X.; Zhang, Z. M.; Liu, F.; Wang, W.; Yu, F.; Lin, Y. H.; Jiang, H. Y.; He, Z. Y. Metamorphic rocks of the causes of southeastern lhasa terrane and the Mesozoic-Cenozoic orogeny. *Acta Petrol. Sin.* **2012**, *28*, 1765–1784.
- (138) Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular properties that influence the oral bioavailability of drug candidates. *J. Med. Chem.* **2002**, *45*, 2615–2623.
- (139) Kelder, J.; Grootenhuis, P. D. J.; Bayada, D. M.; Delbressine, L. P. C.; Ploemen, J. P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. *Pharm. Res.* **1999**, 1514–1519.
- (140) Pajouhesh, H.; Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs. *NeuroRx.* **2005**, *2*, 541–553.
- (141) Waterhouse, R. N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. *Mol. Imaging Biol.* **2003**, *5*, 376–389.

- 
- (142) Wang, Q.; Rager, J. D.; Weinstein, K.; Kardos, P. S.; Dobson, G. L.; Li, J.; Hidalgo, I. J. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. *Int. J. Pharm.* **2005**, *288*, 349–359.
- (143) Chow, A. W. Polysubstituted as-triazino(5,6-*b*)indoles. U.S. Patent No. 3,637,687, **1972**.
- (144) Rydberg, P.; Gloriam, D. E.; Zaretzki, J.; Breneman, C.; Olsen, L. SMARTCyp: A 2D method for prediction of cytochrome P450-mediated drug metabolism. *ACS Med. Chem. Lett.* **2010**, *1*, 96–100.
- (145) Rydberg, P.; Gloriam, D. E.; Olsen, L. The SMARTCyp cytochrome P450 metabolism prediction server. *Bioinformatics* **2010**, *26*, 2988–2989.
- (146) Zaretzki, J.; Matlock, M.; Swamidass, S. J. XenoSite: Accurately predicting CYP-mediated sites of metabolism with neural networks. *J. Chem. Inf. Model.* **2013**, *53*, 3373–3383.
- (147) Hussain, F. H.; Hussein, K. A. K. Synthesis and characterization of some new symmetrical *bis*-isatins derived from *p*-substituted aromatic amines. *Eurasian J. Sci. Eng.* **2018**, *4*.
- (148) Wang, Z. Sandmeyer isatin synthesis. *Comprehensive Organic Name Reactions and Reagents 3*. **2010**, 2467–2470.
- (149) Jeankumar, V. U.; Alokam, R.; Sridevi, J. P.; Suryadevara, P.; Matikonda, S. S.; Peddi, S.; Sahithi, S.; Alvala, M.; Yogeewari, P.; Sriram, D. Discovery and structure optimization of a series of isatin derivatives as *Mycobacterium tuberculosis* chorismate mutase inhibitors. *Chem. Biol. Drug Des.* **2014**, *83*, 498–506.
- (150) S. Tsutsumi, L.; Gündisch, D.; Sun, D. Carbazole scaffold in medicinal chemistry and natural products: a review from 2010-2015. *Curr. Top. Med. Chem.* **2016**, *16*, 1290–1313.
- (151) Yang, W.; Wong, Y.; Ng, O. T. W.; Bai, L. P.; Kwong, D. W. J.; Ke, Y.; Jiang, Z. H.; Li, H. W.; Yung, K. K. L.; Wong, M. S. Inhibition of beta-amyloid peptide aggregation by multifunctional carbazole-based fluorophores. *Angew. Chemie* **2012**, *124*, 1840–1846.

- 
- (152) Naik, N.; Vijay Kumar, H.; Swetha, H. Synthesis and evaluation of novel carbazole derivatives as free radical scavengers. *Bulg. Chem. Commun.* **2010**, *42*, 40–45.
- (153) Saengkhae, C.; Salerno, M.; Adès, D.; Siove, A.; Le Moyec, L.; Migonney, V.; Garnier-Suillerot, A. Ability of carbazole salts, inhibitors of Alzheimer  $\beta$ -amyloid fibril formation, to cross cellular membranes. *Eur. J. Pharmacol.* **2007**, *559*, 124–131.
- (154) Phan, H. T. T.; Samarat, K.; Takamur, Y.; Azo-Oussou, A. F.; Nakazono, Y.; Vestergaard, M. C. Polyphenols modulate Alzheimer's amyloid beta aggregation in a structure-dependent manner. *Nutrients* **2019**, *11*.
- (155) Singh, N.; Agrawal, M.; Doré, S. Neuroprotective properties and mechanisms of resveratrol in *in vitro* and *in vivo* experimental cerebral stroke models. *ACS Chem. Neurosci.* **2013**, *4*, 1151–1162.
- (156) Azman, N. A. M.; Gordon, M. H.; Skowrya, M.; Segovia, F.; Almajano, M. P. Antioxidant properties of resveratrol: a structure-activity insight. *J. Sci. Food Agric.* **2015**, *95*, 210–218.
- (157) Zhang, Z.; Tang, L.; Fan, X.; Wang, Y.; Zhang, K.; Sun, Q.; Zhang, H.; Xue, S.; Yang, W. *N*-Alkylcarbazoles: homolog manipulating long-lived room-temperature phosphorescence. *J. Mater. Chem. C.* **2018**, *6*, 8984–8989.
- (158) Han, W.; Shi, Y.; Xue, T.; Wang, T. Synthesis and electrochemical, linear and third-order nonlinear optical properties of ferrocene-based D- $\pi$ -A dyes as novel photoredox catalysts in photopolymerization under visible LED irradiations. *Dye. Pigment.* **2019**, *166*, 140–148.
- (159) Xue, P.; Wang, P.; Yao, B.; Sun, J.; Gong, P.; Zhang, Z.; Lu, R. Photocurrent generation of nanofibers constructed using a complex of a gelator and a fullerene derivative. *RSC Advances.* **2015**, *5*, 75425–75433.
- (160) Ismail, T.; Shafi, S.; Srinivas, J.; Sarkar, D.; Qurishi, Y.; Khazir, J.; Alam, M. S.; Kumar, H. M. S. Synthesis and tyrosinase inhibition activity of *trans*-stilbene derivatives. *Bioorg. Chem.* **2016**, *64*, 97–102.
- (161) Sammet, B. 4-Nitrophenyl chloroformate: a versatile coupling reagent. *Synlett* **2009**, *18*, 3050–3051.
-

- 
- (162) Robertson, G. R. *p*-Nitrophenylacetic acid. *Org. Synth.* **1922**, 2, 59.
- (163) Cen, M. J.; Wang, Y.; He, Y. W. Microwave assisted synthesis of *trans*-4-nitrostilbene derivatives in solvent free condition. *Eur. J. Chem.* **2017**, 8, 13–14.
- (164) Venkatachalam, T. K.; Uckun, F. M. Synthesis of substituted heterocyclic thiourea compounds. *Synth. Commun.* **2007**, 37, 3667–3675.
- (165) Wang, Z.; Wang, Y.; Wang, B.; Li, W.; Huang, L.; Li, X. Design, synthesis, and evaluation of orally available clioquinol-moracin M hybrids as multitarget-directed ligands for cognitive improvement in a rat model of neurodegeneration in Alzheimer's disease. *J. Med. Chem.* **2015**, 58, 8616–8637.
- (166) Savelieff, M. G.; Lee, S.; Liu, Y.; Lim, M. H. Untangling amyloid- $\beta$ , tau, and metals in Alzheimer's disease. *ACS Chem. Biol.* **2013**, 8, 856–865.
- (167) Shen, Y.; Chen, C. F. Helicenes: synthesis and applications. *Chem. Rev.* **2012**, 112, 1463–1535.
- (168) Mousawi, A. Al; Garra, P.; Dumur, F.; Bui, T. T.; Goubard, F.; Toufaily, J.; Hamieh, T.; Graff, B.; Gigmès, D.; Fouassier, J. P.; Novel carbazole skeleton-based photoinitiators for LED polymerization and LED projector 3D printing. *Molecules* **2017**, 22, 2143.
- (169) Talele, H. R.; Chaudhary, A. R.; Patel, P. R.; Bedekar, A. V. Expedient synthesis of helicenes using an improved protocol of photocyclodehydrogenation of stilbenes. *Arkivoc* **2011**, 9, 15–37.
- (170) Maejima, T.; Shimoda, Y.; Nozaki, K.; Mori, S.; Sawama, Y.; Monguchi, Y.; Sajiki, H. One-pot aromatic amination based on carbon-nitrogen coupling reaction between aryl halides and azido compounds. *Tetrahedron* **2012**, 68, 1712–1722.
- (171) Constant, J. F.; Carden, B. M.; Lhomme, J. Synthetic models related to DNA intercalating molecules: preparation of 9-aminoacridines linked to the nucleotide bases adenine, guanine and thymine. *J. Heterocycl. Chem.* **1985**, 22, 1035–1040.

- 
- (172) Ignasik, M.; Bajda, M.; Guzior, N.; Prinz, M.; Holzgrabe, U.; Malawska, B. Design, synthesis and evaluation of novel 2-(aminoalkyl)-isoindoline-1,3-dione derivatives as dual-binding site acetylcholinesterase inhibitors. *Arch. Pharm. (Weinheim)*. **2012**, *345*, 509–516.
- (173) Ribeiro, N. M.; da Silva, B. V.; de Almeida Violante, F.; Rezende, C. M.; Pinto, A. C. 5-Chloro- and 5,7-dichloroisatin by chlorination of isatin with trichloroisocyanuric acid. *ChemInform*. **2005**, *36*, 265–267.
- (174) Seong, C. M.; Park, W. K.; Park, C. M.; Kong, J. Y.; & Park, N. S. Discovery of 3-aryl-3-methyl-1*H*-quinoline-2,4-diones as a new class of selective 5-HT<sub>6</sub> receptor antagonists. *Bioorg. Med. Chem. Lett*. **2008**, *18*, 738–743.
- (175) Sai Prathima, P.; Bikshapathi, R.; Rao, V. J. Synthesis of isatin derivatives under metal free conditions using hypervalent iodine. *Tetrahedron Lett*. **2015**, *56*, 6385–6388.
- (176) Kollmar, M.; Parlitz, R.; Oevers, S. R.; Hellmchen, G. 2-Amino-3-fluorobenzoic acid: benzoic acid, 2-amino-3-fluoro. *Org. Synth*. **2002**, *79*, 196.
- (177) Meng, G.; Liu, C.; Qin, S.; Dong, M.; Wei, X.; Zheng, M.; Qin, L.; Wang, H.; He, X.; Zhang, Z. An improved synthesis of sunitinib malate via a solvent-free decarboxylation process. *Res. Chem. Intermed*. **2015**, *41*, 8941–8954.
- (178) Senadi, G. C.; Hu, W. P.; Boominathan, S. S. K.; Wang, J. J. Palladium(0)-catalyzed single and double isonitrile insertion: a facile synthesis of benzofurans, indoles, and isatins. *Chem. - A Eur. J*. **2015**, *21*, 998–1003.
- (179) Wilcox, C. F.; Farley, E. N. Dicyclooctabiphenylene. synthesis and properties. *J. Am. Chem. Soc*. **1984**, *106*, 7195–7200.
- (180) Yoshino, T.; Shibata, K.; Wada, H.; Bando, Y.; Ishikawa, K.; Takezoe, H.; Mori, T. Organic field-effect transistors based on solution-processible dibenzotetrathiafulvalene derivatives. *Chem. Lett*. **2009**, *38*, 200–201.
- (181) Li, D.; Wu, P.; Guo, D.; Yu, Y.; Xiao, H.; Jiang, X. Synthesis and luminescence properties of novel carbazolyl-containing amino alcohol

- 
- schiff bases. *Res. Chem. Intermed.* **2015**, *41*, 2591–2601.
- (182) Vadagaonkar, K. S.; Yang, C. J.; Zeng, W. H.; Chen, J. H.; Patil, B. N.; Chetti, P.; Chen, L. Y.; Chaskar, A. C. Triazolopyridine hybrids as bipolar host materials for green phosphorescent organic light-emitting diodes (OLEDs). *Dye. Pigment.* **2019**, *160*, 301–314.
- (183) Nagarajan, R.; Muralidharan, D.; Perumal, P. T. A new and facile method for the synthesis of nitrocarbazoles by urea nitrate. *Synth. Commun.* **2004**, *34*, 1259–1264.
- (184) Jiang, X. K.; Ji, G. Z.; Wang, D. Z. R. The spin-delocalization substituent parameter  $\sigma_{JJ^{\bullet}}$ . part 10. the spin-delocalizing abilities of the *para*-trifluorovinyl and *para*-acetoxy groups. synthesis of *para*-trifluorovinyl-, *para*-vinyl-and *para*-acetoxy- $\alpha,\beta,\beta$ -trifluorostyrenes. *J. Fluor. Chem.* **1996**, *79*, 173–178.